|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122.
|
21402708 |
2011 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
With regard to liver diseases, miR-122 was shown to stimulate hepatitis C virus (HCV) replication through a unique and unusual interaction with two binding sites in the 5'-UTR of HCV genome to mediate the stability of the viral RNA, whereas inhibit the expression and replication of hepatitis B virus (HBV) by a miR-122-cylin G1/p53-HBV enhancer regulatory pathway.
|
22610888 |
2012 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study demonstrates that mice with a targeted deletion of the Mir122a gene possess several key phenotypes of human liver diseases, which provides a rationale for the development of a unique therapy for the treatment of chronic liver disease and HCC.
|
22820290 |
2012 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of miR-122 is also emerging in other liver diseases.
|
23689081 |
2013 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors.
|
23745562 |
2013 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-122 was measured by quantitative PCR in healthy volunteers and patients with liver disease.
|
23547815 |
2013 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-122 (miR-122), a pivotal liver-specific miRNA, has been implicated in several liver diseases including hepatocellular carcinoma (HCC) and hepatitis C and B viral infection.
|
23703729 |
2013 |
|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to investigate the expression and clinical significance of miR-122 and miR-29 in liver disease related to hepatitis B virus infection.
|
25299106 |
2014 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the liver appears to be an important source of circulating EVs in NAFLD animals as evidenced by the enrichment in blood with miR-122 and 192--two microRNAs previously described in chronic liver diseases, coupled with a corresponding decrease in expression of these microRNAs in the liver.
|
25470250 |
2014 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we discuss function and clinical implications of microRNA-122 and other microRNAs in liver diseases, especially viral hepatitis.
|
24642660 |
2014 |
|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The same expression pattern was observed in different stages and grades of liver disease. miR-122 was up-regulated in women relative to men and associated to portal inflammation, miR-122 and miR-126 correlated with serum HCV load and miR-136 and miR-122 correlated with the presence of steatosis. miR-126 and miR-136 were differentially expressed between different modes of HCV transmission.
|
25065618 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir.
|
25537773 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, alterations in intrahepatic miRNA networks have been associated with liver disease including hepatitis, steatosis, cirrhosis and hepatocellular carcinoma (HCC). miR-122 is the most frequent miRNA in the adult liver, and a central player in liver biology and disease.
|
25308172 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-122 (miR-122) is involved in the pathogenesis of several liver diseases, including chronic hepatitis B infection and hepatocellular carcinoma.
|
25766860 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Negative correlations were observed in the fibrosis samples of mixed etiology between miR-122 and fibrosis stage and LS values (P < 0.05), and in the samples of chronic viral hepatitis, between miR-221 and fibrosis stage (P < 0.01), whereas miR-21 showed positive correlation with ALT values in the samples of autoimmune liver diseases (P < 0.03).
|
26167081 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our study indicates that miR-122 may downregulate cytokine production in HSCs and macrophage chemotaxis and that the targeting of miR-122 may have therapeutic potential for preventing the progression of liver diseases.
|
26636761 |
2015 |
|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, hepatic expression of miR-122 does not seem to correspond to progression of the liver disease.
|
27390784 |
2016 |
|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time polymerase chain reaction was utilized to determine serum miR-122 expression in 102 patients with different liver diseases [CHBLF (n = 58), acute hepatitis B (n = 10), chronic hepatitis B (n = 22) and hepatitis B-related cirrhosis (n = 12)] and 23 healthy controls.
|
27059663 |
2016 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
While this study is hypothesis generating, it shows clearly that both miR-122 and miR-200a are promising novel biomarkers for liver disease in the ART-treated, HIV-1-infected population.
|
28883647 |
2017 |
|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On day 28, mice with ethanol-induced liver disease and advanced fibrosis, and controls, were given injections of recombinant adeno-associated virus 8 vector that expressed the primary miR-122 transcript (pri-MIR122, to overexpress MIR122 in hepatocytes) or vector (control).
|
28987423 |
2018 |
|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on our analysis of fold-change in gene expression as a function of disease stage (i.e., early vs. advanced), coupled with consideration of the known relevant functions of these genes, we focused on four candidate genes, ACSL4, GNMT, IFI27, and miR122, which are expressed stage-specifically in HCV mono- and HIV-1/HCV co-infective liver disease and are known to play a pivotal role in regulating HCV-mediated hepatocellular carcinoma (HCC).
|
30138348 |
2018 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Given this fact, EV-associated ncRNAs, such as miR-192, miR-122 and lncRNA-ROR and so on, can serve as new diagnostic biomarkers and new therapeutic targets for liver disease, because altered EV-associated ncRNAs may reflect the underlying liver disease condition.
|
29740327 |
2018 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have demonstrated that miR-122 is a valuable therapeutic target for liver diseases, including viral hepatitis, fibrosis, steatosis, and hepatocarcinoma.
|
29627726 |
2018 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-122 (miR-122) is associated with various liver diseases.
|
29922759 |
2018 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-122 is well recognized as a promising therapeutic target in liver disease, whereas recently plays important roles in cardiovascular diseases.
|
31543343 |
2019 |